IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC), a key player in the international medical cannabis market, reported its financial results for the first quarter of 2025, demonstrating a remarkable turnaround with a net profit of $175,000. This marks a significant improvement from a net loss of $6 million in the same quarter of 2024.<\/p>\n\n\n\n
In the first quarter of 2025, IM Cannabis generated revenues of $12.5 million, a 4% increase compared to $12.1 million in Q1 2024. This growth is attributed to a surge in sales in Germany, where revenues reached $6.6 million, offsetting a decline in Israeli sales of $6.1 million. The company\u2019s gross profit also saw impressive growth, rising 94% to $3.5 million from $1.8 million year-over-year.<\/p>\n\n\n\n
Operating expenses were reduced substantially, dropping 50% to $3.3 million when excluding a one-time loss of $3.3 million related to the Oranim revocation. Including the Oranim impact, total operating expenses decreased by 56%. General and administrative expenses decreased to $2 million from $2.3 million, while selling and marketing expenses fell by 44% to $1.3 million.<\/p>\n\n\n\n
The company’s gross margin improved dramatically, reaching 87%, up from 46% in Q1 2024. Non-IFRS Adjusted EBITDA turned positive, increasing 129% to $0.6 million, compared to a loss of $2.2 million in Q1 2024. The operating ratio improved from 77% to 26%, indicating better cost management and operational effectiveness.<\/p>\n\n\n\n
Oren Shuster, CEO of IM Cannabis, stated, “Q1 2025 is a clear inflection point for IMC. Achieving net profitability and an 87% improvement in gross margin year-over-year demonstrates the strength of the strategic and operational groundwork we laid in 2024 and reinforces our trajectory toward sustained, profitable growth.” <\/p>\n\n\n\n
Uri Birenberg, CFO of IM Cannabis, noted the importance of these results, emphasizing the company’s focus on reducing operational costs while increasing revenue. As of March 31, 2025, the company reported total assets of $44.9 million, up 15% from the previous quarter, largely due to increased trade receivables and inventory.<\/p>\n\n\n\n
To bolster its financial position, IM Cannabis plans to undertake a non-brokered private placement of secured convertible debentures, aiming for proceeds of up to C$2.5 million. These debentures will mature in 12 months and may convert into common shares at a later date.<\/p>\n\n\n\n
The company is set to hold a conference call via Zoom to discuss its Q1 2025 results, inviting investors to register and participate in a question-and-answer session. A recording will be available on their investor relations website shortly after.<\/p>\n\n\n\n
IM Cannabis continues to solidify its presence in the medical cannabis sector, operating primarily in Israel and Germany. The company is committed to responsible growth while navigating the complex regulatory environments of these markets. Through its subsidiaries, it imports and distributes cannabis products and operates medical cannabis retail pharmacies, ensuring quality control throughout its supply chain. IM Cannabis is well-positioned to capitalize on the growing demand for medical cannabis as markets continue to expand.<\/p>","protected":false},"excerpt":{"rendered":"
Spole\u010dnost IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC), kl\u00ed\u010dov\u00fd hr\u00e1\u010d na mezin\u00e1rodn\u00edm trhu s l\u00e9\u010debn\u00fdm konop\u00edm, ozn\u00e1mila sv\u00e9 finan\u010dn\u00ed v\u00fdsledky...<\/p>","protected":false},"author":2,"featured_media":5970,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[46],"tags":[1854,142,1993,1992],"class_list":["post-5971","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-financials","tag-germany","tag-israel","tag-profits"],"yoast_head":"\n